{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:01:50Z","timestamp":1784718110144,"version":"3.55.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.nbd.2024.106452","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T17:07:32Z","timestamp":1708708052000},"page":"106452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Suppression of presynaptic corticostriatal glutamate activity attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's disease mice"],"prefix":"10.1016","volume":"193","author":[{"given":"Yu-Ting","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tze-Yen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Chung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2024.106452_bb0005","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/14728214.2020.1763954","article-title":"Emerging drugs for the treatment of L-DOPA induced dyskinesia: an update","volume":"25","author":"Alshimemeri","year":"2020","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.nbd.2024.106452_bb0010","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/mds.26125","article-title":"Clinical spectrum of levodopa-induced complications","volume":"30","author":"Aquino","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2024.106452_bb0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bbr.2018.08.013","article-title":"Tat-Src reduced NR2B tyrosine phosphorylation and its interaction with NR2B in levodopa-induced dyskinetic rats model","volume":"356","author":"Ba","year":"2019","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.nbd.2024.106452_bb0020","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.07.002","article-title":"Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson\u2019s disease","volume":"132","author":"Bastide","year":"2015","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.nbd.2024.106452_bb0025","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/mds.25920","article-title":"The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model","volume":"29","author":"Bezard","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2024.106452_bb0030","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/mds.870130507","article-title":"Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys","volume":"13","author":"Blanchet","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2024.106452_bb0035","first-page":"1","article-title":"Fyn knock-down prevents levodopa-induced dyskinesia in a mouse model of Parkinson\u2019s disease","volume":"8","author":"Bordone","year":"2021","journal-title":"eNeuron"},{"key":"10.1016\/j.nbd.2024.106452_bb0040","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/mds.20612","article-title":"Nondopaminergic mechanisms in levodopa-induced dyskinesia","volume":"20","author":"Brotchie","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2024.106452_bb0045","first-page":"S96","article-title":"FP0011 extends the duration of the anti-parkinsonian actions of L-DOPA and reduces L-DOPA-induced dyskinesia in the MPTP-lesiones macaque model of Parkinson\u2019s disease","volume":"22","author":"Brotchie","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2024.106452_bb0050","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nbd.2015.10.020","article-title":"Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia","volume":"85","author":"Brugnoli","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2024.106452_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105697","article-title":"Striatal glutamatergic hyperactivity in Parkinson's disease","volume":"168","author":"Campanelli","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2024.106452_bb0060","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuroscience.2011.07.070","article-title":"Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia","volume":"198","author":"Carta","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2024.106452_bb0065","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00702-018-1865-5","article-title":"The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective","volume":"125","author":"Carta","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.nbd.2024.106452_bb0070","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.conb.2008.01.004","article-title":"Advances in understanding L-DOPA-induced dyskinesia","volume":"17","author":"Cenci","year":"2007","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.nbd.2024.106452_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109027","article-title":"Non-dopaminergic approaches to the treatment of motor complications in Parkinson\u2019s disease","volume":"210","author":"Cenci","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nbd.2024.106452_bb0080","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/ijms21010294","article-title":"L-DOPA in Parkinson\u2019s disease: looking at the \u201cfalse\u201d neurotransmitters and their meaning","volume":"21","author":"Chagraoui","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.nbd.2024.106452_bb0085","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.neuropharm.2018.03.027","article-title":"mGlu4 allosteric modulation for treating Parkinson\u2019s disease","volume":"135","author":"Charvin","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nbd.2024.106452_bb0090","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/mds.27077","article-title":"Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine Parkinson\u2019s disease model","volume":"32","author":"Chotibut","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2024.106452_bb0095","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.parkreldis.2018.10.005","article-title":"Naftazone in advanced Parkinson\u2019s disease: an acute L-DOPA challenge randomized controlled trial","volume":"60","author":"Corvol","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.nbd.2024.106452_bb0100","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1038\/s41467-022-30844-0","article-title":"Cerebellar stimulation prevents levodopa-induced dyskinesia in mice and normalizes activity in a motor network","volume":"13","author":"Coutant","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.nbd.2024.106452_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2015.11.009","article-title":"Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's disease","volume":"86","author":"Dupre","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2024.106452_bb0110","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41582-019-0155-7","article-title":"Emerging therapies in Parkinson disease \u2014 repurposed drugs and new approaches","volume":"15","author":"Elkouzi","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.nbd.2024.106452_bb0115","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ana.25364","article-title":"Levodopa- induced dyskinesia in Parkinson disease: current and evolving concepts","volume":"84","author":"Espay","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2024.106452_bb0120","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2147\/JEP.S265282","article-title":"Pathophysiological mechanisms and experimental pharmacotherapy for L-Dopa-induced dyskinesia","volume":"13","author":"Fabbrini","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"10.1016\/j.nbd.2024.106452_bb0125","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1038\/ncomms6316","article-title":"Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia","volume":"5","author":"Fieblinger","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.nbd.2024.106452_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.783893","article-title":"Striatal D1 dopamine neuronal population dynamics in a rat model of levodopa-induced dyskinesia","volume":"14","author":"Gao","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.nbd.2024.106452_bb0135","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1523\/JNEUROSCI.5326-05.2006","article-title":"A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia","volume":"26","author":"Gardoni","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2024.106452_bb0140","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1124\/jpet.118.251645","article-title":"Safinamide modulates striatal glutamatergic signaling in a rat model of levodopa-induced dyskinesia","volume":"367","author":"Gardoni","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.nbd.2024.106452_bb0145","first-page":"17","article-title":"The nigrostriatal system in Parkinson\u2019s disease","volume":"53","author":"Graybiel","year":"1990","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.nbd.2024.106452_bib316","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.brs.2019.06.012","article-title":"Abnormal cortical facilitation and L-dopa-induced dyskinesia in Parkinson\u2019s disease","volume":"12","author":"Guerra","year":"2019","journal-title":"Brain Stim"},{"key":"10.1016\/j.nbd.2024.106452_bb0150","doi-asserted-by":"crossref","first-page":"11589","DOI":"10.1073\/pnas.1304365110","article-title":"Optogenetic dissection reveals multiple rhythmogenic modules underlying locomotion","volume":"110","author":"H\u00e4gglunda","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.nbd.2024.106452_bb0155","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/mds.26947","article-title":"Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease","volume":"32","author":"Hernandez","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2024.106452_bb0160","first-page":"29558","article-title":"Substantia nigra pars reticulata projections to the pedunculopontine nucleus modulate dyskinesia","author":"Hu","year":"2023","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2024.106452_bb0165","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/pr.111.005678","article-title":"The pharmacology of L-DOPA-induced dyskinesia in Parkinson\u2019s disease","volume":"65","author":"Huot","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.nbd.2024.106452_bb0170","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/archneur.57.3.369","article-title":"The evolution of diagnosis in early Parkinson disease. Parkinson study group","volume":"57","author":"Jankovic","year":"2000","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.nbd.2024.106452_bb0175","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1111\/bph.14663","article-title":"Optostimulation of striatonigral terminals in substantia nigra induces dyskinesia that increases after L-DOPA in a mouse model of Parkinson's disease","volume":"176","author":"Keifman","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.nbd.2024.106452_bb0180","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1007\/s00213-013-3400-6","article-title":"The effects of the \u03b2-lactam antibiotic, ceftriaxone, on forepaw stepping and L-dopa-induced dyskinesia in a rodent model of Parkinson\u2019s disease","volume":"231","author":"Kelsey","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.nbd.2024.106452_bb0185","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.parkreldis.2014.01.016","article-title":"Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson\u2019s disease","volume":"20","author":"Kobylecki","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.nbd.2024.106452_bb0190","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/mds.20360","article-title":"Levodopa-dyskinesia incidence by age of Parkinson's disease onset","volume":"20","author":"Kumar","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2024.106452_bb0195","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.3390\/cells11233736","article-title":"Levodopa-induced dyskinesia in Parkinson\u2019s disease: pathogenesis and emerging treatment strategies","volume":"11","author":"Kwon","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.nbd.2024.106452_bb0200","first-page":"12264","article-title":"The dynamics of dopamine D2 receptor-expressing striatal neurons and the downstream circuit underlying L-Dopa-induced dyskinesia in rats","author":"Liu","year":"2023","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.nbd.2024.106452_bb0205","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/glia.10310","article-title":"Glutamate transporter expression and function in human glial progenitors","volume":"45","author":"Maragakis","year":"2004","journal-title":"Glia"},{"key":"10.1016\/j.nbd.2024.106452_bb0210","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1113\/JP278747","article-title":"Excitation, but not inhibition, of the fastigial nucleus provides powerful control over temporal lobe seizures","volume":"598","author":"Martha","year":"2020","journal-title":"J. Physiol."},{"key":"10.1016\/j.nbd.2024.106452_bb0215","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00702-018-1846-8","article-title":"Glutamatergic mechanisms in l-DOPA-induced dyskinesia and therapeutic implications","volume":"125","author":"Mellone","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.nbd.2024.106452_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055706","article-title":"Striatal glutamate release in L-DOPA-induced dyskinetic animals","volume":"8","author":"Nevalainen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2024.106452_bb0225","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/mds.27172","article-title":"Levodopa treatment and dendritic spine pathology","volume":"33","author":"Nishijima","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2024.106452_bb0230","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jocn.2021.05.056","article-title":"The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson\u2019s disease: clinical cases and a review of the literature","volume":"90","author":"Pagonabarraga","year":"2021","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.nbd.2024.106452_bb0235","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/mds.26326","article-title":"Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity","volume":"30","author":"Paolone","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2024.106452_bb0240","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/j.parkreldis.2015.09.004","article-title":"Non-motor symptoms in Parkinson\u2019s disease","volume":"22","author":"Pfeiffer","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.nbd.2024.106452_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109411","article-title":"Serotonin 5-HT1A receptors and their interactions with adenosine A2A receptors in Parkinson\u2019s disease and dyskinesia","volume":"226","author":"Pinna","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nbd.2024.106452_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108163","article-title":"Comparing dopamine release, uptake, and D2 autoreceptor function across the ventromedial to dorsolateral striatum in adolescent and adult male and female rats","volume":"175","author":"Pitts","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nbd.2024.106452_bb0255","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1468-1331.2008.02056.x","article-title":"Non-motor symptoms in Parkinson\u2019s disease","volume":"1","author":"Poewe","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.nbd.2024.106452_bb0260","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/B978-0-12-381328-2.00002-X","article-title":"L-Dopa-induced dyskinesia\u2014clinical presentation, genetics, and treatment","volume":"98","author":"Prashanth","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.nbd.2024.106452_bb0265","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ana.22097","article-title":"Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia","volume":"68","author":"Rylander","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2024.106452_bb0270","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3233\/JPD-130186","article-title":"Levodopa in the treatment of Parkinson\u2019s disease: current status and new developments","volume":"3","author":"Salat","year":"2013","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.nbd.2024.106452_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105650","article-title":"Striatal synaptic dysfunction in dystonia and levodopa-induced dyskinesia","volume":"166","author":"Scarduzio","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2024.106452_bb0280","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.nbd.2016.09.001","article-title":"Validation of an improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists","volume":"96","author":"Sebastianutto","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2024.106452_bb0285","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1007\/s00018-015-1937-8","article-title":"Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease","volume":"72","author":"Takahashi","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.nbd.2024.106452_bb0290","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41586-022-05144-8","article-title":"The whisking oscillator circuit","volume":"609","author":"Takatoh","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2024.106452_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neures.2007.05.002","article-title":"Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in parkinsonian model rats","volume":"59","author":"Yamada","year":"2007","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.nbd.2024.106452_bb0300","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1177\/0271678X21994395","article-title":"Activation of astroglial CB1R mediates cerebral ischemic tolerance induced by electroacupuncture","volume":"41","author":"Yang","year":"2021","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.nbd.2024.106452_bb0305","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neuroscience.2023.02.004","article-title":"ONO-2506 can delay levodopa-induced dyskinesia in the early stage","volume":"523","author":"Yuan","year":"2023","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2024.106452_bb0310","doi-asserted-by":"crossref","first-page":"11655","DOI":"10.1523\/JNEUROSCI.0288-13.2013","article-title":"Aberrant restoration of spines and their synapses in L-DOPA-induced dyskinesia: involvement of corticostriatal but not thalamostriatal synapses","volume":"33","author":"Zhang","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2024.106452_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104807","article-title":"Distinct anti-dyskinetic effects of amantadine and group II metabotropic glutamate receptor agonist LY354740 in a rodent model: an electrophysiological perspective","volume":"139","author":"Zheng","year":"2020","journal-title":"Neurobiol. Dis."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996124000512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996124000512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:47:58Z","timestamp":1725583678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996124000512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":64,"alternative-id":["S0969996124000512"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2024.106452","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suppression of presynaptic corticostriatal glutamate activity attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's disease mice","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2024.106452","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106452"}}